Artal Group’s Oric Pharmaceuticals ORIC Stock Holding History

Artal Group’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400,000	Closed	-$2.36M	–	135
2022 Q4	$2.36M	Hold	400,000	–	–	0.14%	83
2022 Q3	$1.28M	Hold	400,000	–	–	0.07%	106
2022 Q2	$1.79M	Hold	400,000	–	–	0.1%	103
2022 Q1	$2.14M	Hold	400,000	–	–	0.09%	111
2021 Q4	$5.88M	Hold	400,000	–	–	0.17%	97
2021 Q3	$8.36M	Hold	400,000	–	–	0.21%	90
2021 Q2	$7.08M	Buy	400,000 +300,000	+300%	+$6.57M	0.16%	110
2021 Q1	$2.45M	Hold	100,000	–	–	0.05%	138
2020 Q4	$3.38M	Sell	100,000 -42,500	-30%	-$1.22M	0.08%	116
2020 Q3	$3.56M	Sell	142,500 -7,500	-5%	-$179K	0.12%	108
2020 Q2	$5.06M	Buy	+150,000	New	+$4.79M	0.17%	105

Other funds holding ORIC

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return

Alkeon Capital Management

Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return